Publishing: May 2021 | Report Code: LS10158 | Available Format: PDF
Diabetic retinopathy refers to an eye disorder that damages or harms the blood vessels of the retina. Diabetic retinopathy can cause permanent blindness. Chronic diabetes is a major root of diabetic retinopathy. High glucose level in the blood can damage blood vessels in the retina. Diabetic retinopathy can also cause diabetic macular edema: a medical condition led to the leakage of fluid from the previously injured blood vessels or minute or delicate blood vessels near the back of the eye, this disease can result in inflammation near the eye and blurred vision.
The treatment procedure of diabetic retinopathy depends on the various stages of diabetic retinopathy. It is one of the most dominant reasons of blindness in U.S adults. According to WHO, about 347 million patients were suffering from diabetes globally as of 2012, and among those 347 million patients 11% of those were effected from diabetic retinopathy. In the U.S. alone, there were 4.1 million people were impacted from the diabetic retinopathy as of 2012.
North America was the largest market for diabetic retinopathy in 2014. The market dominance of North America is attributed to the high obesity rate and large diabetic patients in this region. Moreover the supportive government initiative is also one of the important drivers of the market in this region. Europe was the second largest market of diabetic retinopathy in 2014, the large population of baby boomers in Europe is one of the dominate growth factors for the diabetic retinopathy market in this region. Asia Pacific is expected to show the highest growth over the next five years. The lucrative growth of the diabetic retinopathy market in Asia Pacific is attributed to the presence of a large number of diabetic patients in India and China. Moreover, growing health awareness coupled with rising expenditure on healthcare services is also fueling the diabetic retinopathy market in this region. Country wise the U.S. is the largest market of diabetic retinopathy in North America. Germany, Spain, Italy, U.K and France are some of the major diabetic retinopathy market in Europe. China, Japan, India are some of the major market diabetic retinopathy in Asia Pacific region. Under Rest of the World section Brazil is the largest market of diabetic retinopathy.
Global increase in the diabetes patients, large population of baby boomers, and changing lifestyle in developing countries are some of the dominant factors driving diabetic retinopathy market. In addition the increased health awareness and rising disposable income in developing countries has increased the advanced healthcare services, affordability; which interns driving the market of diabetic retinopathy. The rising awareness towards the treatment of diabetic retinopathy and advancement of patient monitoring through electronic medical record in ophthalmology are some of recent market trend in the diabetic retinopathy market.
Based on the disease type the global diabetic retinopathy market can be broadly classified as non-proliferative diabetic retinopathy, and proliferative retinopathy. Based on the various treatment method the global diabetic retinopathy market cab be broadly classified as Laser surgery, corticosteroids injection, anti-VEGF drugs, and others
Based on the different drug use in the global diabetic retinopathy market the market can be bifurcated as ATL-1103, Lycium Anti-Angiogenic Proteoglycan, ocriplasmin (recombinant), STP-601, BI-30089, OC-10X, and Squalamine Lactate.
Some of the major players operating in the global diabetic retinopathy market include, Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Regeneron Pharmaceuticals Inc., Novartis AG, Valeant Pharmaceuticals International Inc., Abbott Laboratories Ltd., Alimera Sciences Inc., Ampio Pharmaceuticals Inc., Bausch & Lomb Inc., Boehringer Ingelheim GmbH, iCo Therapeutics Inc., Lupin Ltd., Parexel International Corp., Quark Pharmaceuticals Inc., Thrombogenics NV, and Vitreoretinal Technologies Inc.
Our dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws